Stock listing
Stuttgart:NXOA Nicox SA Aktie
German listing (Stuttgart) of Nicox SA · home listing Euronext:ALCOX
Follow Nicox SA into a list and get an email when it puts out news.
Home listing price · EURONEXT:ALCOX
€0.268 EUR -0.013 (-4.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:ALCOX
- Day range
- €0.252 – €0.270 EURNov 20, 2026
- Volume
- 200,019 sharesNov 20, 2026
- Market cap
- €26.47M EURAt the close on Nov 20, 2026 · price × 98.76M shares outstanding
- 52-week range
- €0.252 – €0.569 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €47,737 EURMedian day 108,641 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:ALCOX · Home | €0.268 EUR | -0.013 (-4.8%) | 200,019 | €0.270 | €0.270 | €0.252 | €0.282 | Close on Nov 20, 2026 |
| LSE:0RCQ | €0.264 EUR | -0.017 (-5.9%) | 70 | €0.264 | €0.264 | €0.264 | €0.281 | Close on Nov 20, 2026 |
| Frankfurt:NXOA | €0.218 EUR | +0.011 (+5.3%) | — | €0.200 | €0.218 | €0.200 | €0.207 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:ALCOX · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.268 | -0.013 | -4.8% | €0.270 | €0.270 | €0.252 | 200,019 | |
| €0.282 | -0.001 | -0.2% | €0.288 | €0.288 | €0.282 | 228,494 | |
| €0.282 | -0.004 | -1.4% | €0.286 | €0.289 | €0.282 | 81,691 | |
| €0.286 | -0.001 | -0.3% | €0.290 | €0.290 | €0.286 | 42,063 | |
| €0.287 | -0.003 | -1.0% | €0.297 | €0.297 | €0.287 | 82,753 | |
| €0.290 | -0.006 | -2.0% | €0.296 | €0.305 | €0.290 | 71,413 | |
| €0.296 | +0.008 | +2.8% | €0.294 | €0.310 | €0.293 | 123,707 | |
| €0.288 | +0.001 | +0.3% | €0.290 | €0.291 | €0.286 | 45,382 | |
| €0.287 | +0.002 | +0.7% | €0.289 | €0.290 | €0.284 | 69,793 | |
| €0.285 | +0.003 | +0.9% | €0.283 | €0.292 | €0.283 | 128,245 | |
| €0.283 | +0.001 | +0.4% | €0.282 | €0.290 | €0.282 | 88,304 | |
| €0.282 | +0.000 | +0.2% | €0.282 | €0.290 | €0.282 | 68,479 | |
| €0.281 | -0.009 | -3.1% | €0.291 | €0.292 | €0.281 | 185,815 | |
| €0.290 | -0.009 | -3.0% | €0.316 | €0.316 | €0.285 | 136,318 | |
| €0.299 | -0.011 | -3.5% | €0.313 | €0.324 | €0.295 | 310,746 | |
| €0.310 | 0.000 | 0.0% | €0.314 | €0.314 | €0.303 | 121,427 | |
| €0.310 | -0.010 | -3.0% | €0.301 | €0.318 | €0.301 | 84,647 | |
| €0.320 | +0.019 | +6.1% | €0.301 | €0.320 | €0.296 | 237,207 | |
| €0.301 | +0.008 | +2.6% | €0.290 | €0.303 | €0.290 | 105,874 | |
| €0.294 | +0.001 | +0.3% | €0.293 | €0.294 | €0.287 | 50,801 | |
| €0.293 | -0.004 | -1.2% | €0.293 | €0.297 | €0.289 | 72,056 | |
| €0.296 | -0.007 | -2.3% | €0.292 | €0.300 | €0.292 | 99,872 | |
| €0.303 | +0.006 | +2.0% | €0.303 | €0.303 | €0.281 | 293,009 | |
| €0.297 | -0.003 | -1.0% | €0.295 | €0.297 | €0.293 | 82,389 | |
| €0.300 | +0.005 | +1.7% | €0.300 | €0.300 | €0.295 | 89,432 | |
| €0.295 | +0.005 | +1.7% | €0.290 | €0.307 | €0.290 | 51,334 | |
| €0.290 | -0.011 | -3.5% | €0.300 | €0.301 | €0.290 | 264,337 | |
| €0.301 | -0.002 | -0.7% | €0.303 | €0.306 | €0.300 | 100,962 | |
| €0.303 | -0.007 | -2.1% | €0.310 | €0.312 | €0.303 | 116,357 | |
| €0.309 | +0.014 | +4.7% | €0.314 | €0.314 | €0.305 | 90,645 | |
| €0.295 | -0.018 | -5.8% | €0.312 | €0.312 | €0.295 | 250,705 | |
| €0.313 | -0.005 | -1.6% | €0.317 | €0.320 | €0.310 | 223,490 | |
| €0.318 | -0.008 | -2.5% | €0.327 | €0.327 | €0.316 | 109,104 | |
| €0.326 | +0.005 | +1.4% | €0.324 | €0.328 | €0.322 | 69,781 | |
| €0.322 | -0.004 | -1.1% | €0.320 | €0.327 | €0.318 | 280,187 | |
| €0.325 | -0.009 | -2.7% | €0.344 | €0.344 | €0.325 | 114,849 | |
| €0.334 | -0.006 | -1.8% | €0.335 | €0.344 | €0.332 | 210,549 | |
| €0.340 | +0.006 | +1.6% | €0.339 | €0.345 | €0.334 | 141,180 | |
| €0.335 | 0.000 | 0.0% | €0.335 | €0.338 | €0.335 | 44,057 | |
| €0.335 | -0.003 | -0.9% | €0.337 | €0.344 | €0.334 | 145,907 | |
| €0.338 | +0.002 | +0.4% | €0.336 | €0.340 | €0.336 | 40,939 | |
| €0.336 | -0.007 | -2.0% | €0.345 | €0.345 | €0.333 | 106,432 | |
| €0.343 | +0.002 | +0.4% | €0.341 | €0.347 | €0.341 | 107,637 | |
| €0.342 | +0.006 | +1.6% | €0.340 | €0.349 | €0.336 | 146,455 | |
| €0.336 | +0.006 | +1.7% | €0.331 | €0.340 | €0.330 | 38,279 | |
| €0.331 | +0.004 | +1.1% | €0.327 | €0.334 | €0.325 | 149,848 | |
| €0.327 | -0.005 | -1.4% | €0.338 | €0.338 | €0.327 | 133,497 | |
| €0.332 | -0.004 | -1.0% | €0.340 | €0.340 | €0.330 | 261,240 | |
| €0.335 | -0.009 | -2.6% | €0.340 | €0.344 | €0.330 | 385,535 | |
| €0.344 | -0.012 | -3.4% | €0.366 | €0.366 | €0.339 | 492,385 | |
| €0.356 | -0.013 | -3.5% | €0.370 | €0.370 | €0.356 | 170,301 | |
| €0.369 | -0.007 | -1.9% | €0.377 | €0.377 | €0.363 | 214,565 | |
| €0.376 | +0.001 | +0.3% | €0.377 | €0.383 | €0.374 | 83,632 | |
| €0.375 | -0.006 | -1.6% | €0.381 | €0.384 | €0.370 | 294,126 | |
| €0.381 | -0.005 | -1.3% | €0.386 | €0.388 | €0.381 | 106,909 | |
| €0.386 | +0.002 | +0.4% | €0.389 | €0.389 | €0.382 | 122,798 | |
| €0.385 | +0.002 | +0.4% | €0.385 | €0.390 | €0.382 | 108,178 | |
| €0.383 | -0.006 | -1.5% | €0.388 | €0.388 | €0.381 | 59,905 | |
| €0.389 | +0.004 | +1.0% | €0.388 | €0.390 | €0.383 | 90,111 | |
| €0.385 | -0.005 | -1.2% | €0.380 | €0.385 | €0.379 | 234,776 | |
| €0.390 | +0.010 | +2.6% | €0.395 | €0.395 | €0.381 | 414,664 | |
| €0.380 | -0.001 | -0.3% | €0.381 | €0.384 | €0.379 | 97,776 | |
| €0.381 | -0.002 | -0.5% | €0.385 | €0.385 | €0.380 | 169,554 | |
| €0.383 | 0.000 | 0.0% | €0.381 | €0.383 | €0.381 | 83,441 | |
| €0.383 | -0.001 | -0.1% | €0.382 | €0.384 | €0.381 | 64,180 | |
| €0.383 | -0.001 | -0.3% | €0.383 | €0.386 | €0.381 | 99,045 |
Splits
4 splits since 2002 · EURONEXT:ALCOX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-5 | Consolidation | |
| 51-for-44 | Split | |
| 47-for-44 | Split | |
| 3-for-1 | Split |
- Ticker
- Stuttgart:NXOA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Oct 30, 2026
Nicox Reports First Half 2026 Financial Results
Latest deck · Oct 30, 2026
Investor Presentation (October 2026)
Investor deck · 26 slides
Latest news
Nicox Reports First Half 2026 Financial Results
Oct 30, 2026
Closed €0.299 (-3.5%) on Oct 30, 2026
Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026
Sep 16, 2026
Closed €0.327 (-1.4%) on Sep 16, 2026
Nicox: Les données sur NCX 470 seront présentées lors du Congrès annuel 2026 de l’AAOpt
Sep 15, 2026
Closed €0.327 (-1.4%) on Sep 16, 2026
Nicox Announces NCX 470 NDA in China Accepted for Review
Sep 11, 2026
Closed €0.344 (-3.4%) on Sep 11, 2026
Nicox annonce l’acceptation pour examen en Chine de la NDA de NCX 470
Sep 10, 2026
Closed €0.344 (-3.4%) on Sep 11, 2026
Nicox Announces Extension of Cash Runway
Sep 2, 2026
Closed €0.385 (+0.4%) on Sep 2, 2026
Nicox annonce l’extension de son horizon de trésorerie
Sep 1, 2026
Closed €0.385 (+0.4%) on Sep 2, 2026
Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma
Aug 26, 2026
Closed €0.39 (+2.6%) on Aug 27, 2026
Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension
Aug 9, 2026
Closed €0.388 (+2.0%) on Aug 10, 2026
Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
Jul 1, 2026
Closed €0.374 (-0.9%) on Jul 1, 2026
Nicox SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 33 in all · newest Oct 30, 2026 · oldest 2025
- Decks
- 109 decks · latest Oct 30, 2026
Where Nicox SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:ALCOX · Home listing | Euronext | France | EUR |
| LSE:0RCQ | LSE | United Kingdom | EUR |
| gettex:NXOA | gettex | Germany | EUR |
| LS Exchange:A143G8 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A143G8 | Lang & Schwarz | Germany | EUR |
| OTC:NICXF | OTC | United States | USD |
| Dusseldorf:NXOA | Dusseldorf | Germany | EUR |
| Aquis:ALCOXP | Aquis | United Kingdom | EUR |
| Aquis:ALCOXP | Aquis | United Kingdom | EUR |
| Frankfurt:NXOA | Frankfurt | Germany | EUR |
| Hamburg:NXOA | Hamburg | Germany | EUR |
| Munich:NXOA | Munich | Germany | EUR |
| Stuttgart:NXOA · This page | Stuttgart | Germany | EUR |
| Turquoise:ALCOXP | Turquoise | United Kingdom | EUR |
Valuation
EV/sales 1.4× against a median of 50.2×: 2nd lowest of 3 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €23.40M EUR
- P/E
- Loss
- EV/sales
- 1.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.8×
- Gross margin
- 39.0%
- Operating margin
- −81.3%
- Net margin
- −14.4%
- Debt to equity
- 0.4×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Nicox SA · EURONEXT:ALCOX | US$29.04M | US$25.67M | n/a | 1.4× | n/a | 3.8× | −14.4% | 0.4× | n/a |
| Pacific Software, Inc. · OTC:PFSF | US$29.86M | US$38.10M | n/a | n/a | n/a | n/a | n/a | n/a | 1.57 |
| NextCure, Inc. · NASDAQ:NXTC | US$29.53M | US$20.81M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.85 |
| NurExone Biologic Inc · TSXV:NRX | US$29.53M | US$28.52M | n/a | n/a | n/a | 23.3× | n/a | 0.0× | 0.00 |
| BioHarvest Sciences, Inc. · NASDAQ:BHST | US$29.47M | US$34.54M | n/a | 1.0× | n/a | 1.8× | −34.7% | 1.0× | 0.43 |
| Thiogenesis Therapeutics Corp · TSXV:TTI | US$29.28M | US$24.21M | n/a | n/a | n/a | 6.2× | n/a | 0.0× | 0.37 |
| NanoViricides, Inc. · AMEX:NNVC | US$29.11M | US$26.54M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | 1.82 |
| Rein Therapeutics, Inc. · NASDAQ:RNTX | US$29.06M | −US$6.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 2.11 |
| Serina Therapeutics, Inc. · AMEX:SER | US$28.45M | US$12.42M | n/a | 99.3× | n/a | 2.0× | n/a | 0.2× | 1.60 |
| ProMIS Neurosciences Inc. · NASDAQ:PMN | US$28.43M | −US$15.68M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.83 |
| Entropy Neurodynamics Limited · ASX:ENP | US$28.14M | US$24.44M | n/a | n/a | n/a | 5.8× | n/a | 0.0× | n/a |
| Median of the others | US$29.20M | US$24.33M | 50.2× | 4.5× | −34.7% | 0.0× | 1.57 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.00 EUR · Analysts' mean
- EPS, year to Dec 2026
- -0.050 · 1 analyst
- Revenue, year to Dec 2026
- 3M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Gavin Spencer | Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Damian Marron | Chairman of the Board of Directors |
| Christine Placet | Director |
| Gavin Spencer | Chief Executive Officer |
| Marc Le Bozec | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2025 | Oct 15, 2025 · Before open | +4.1% |
| Q2 2025 | Sep 3, 2025 | −1.2% |
| Quarter to Mar 31, 2025 | Apr 30, 2025 | −4.7% |
| Quarter to Sep 30, 2024 | Oct 17, 2024 | −1.6% |
| Quarter to Mar 31, 2024 | Apr 22, 2024 | −0.5% |
| Q4 2023 | Jan 25, 2024 · Before open | −2.4% |
| Quarter to Sep 30, 2023 | Oct 20, 2023 · Before open | −0.7% |
| Q2 2023 | Jul 19, 2023 · After close | +0.9% |
| Q1 2023 | Apr 19, 2023 · Before open | −9.0% |
| Q4 2022 | Jan 18, 2023 · Before open | −1.1% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2022 | Oct 19, 2022 | +5.4% |
| Q2 2022 | Sep 16, 2022 | −0.3% |
| Quarter to Mar 31, 2022 | Apr 28, 2022 | +1.8% |
| Q4 2021 | Mar 10, 2022 | +3.5% |
| Quarter to Sep 30, 2021 | Oct 19, 2021 | +0.8% |
| Q2 2021 | Sep 27, 2021 | −1.2% |
| Quarter to Mar 31, 2021 | Apr 19, 2021 | −2.6% |
| Q4 2020 | Mar 1, 2021 | −1.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 26 slides | Oct 30, 2026 |
| Investor Presentation (September 2026) | Investor deck | 28 slides | Sep 11, 2026 |
| Investor Presentation (April 2026) | Investor deck | 25 slides | Apr 30, 2026 |
| Investor Presentation (February 2026) | Investor deck | 25 slides | Feb 24, 2026 |
| Investor Presentation (January 2026) | Investor deck | 25 slides | Jan 5, 2026 |
| Investor Presentation (January 2026) | Investor deck | 25 slides | Jan 5, 2026 |
| Investor Presentation (October 2025) | Investor deck | 25 slides | Oct 23, 2025 |
| Investor Presentation (October 2025) | Investor deck | 25 slides | Oct 23, 2025 |
| Investor Presentation (September 2025) | Investor deck | 26 slides | Sep 4, 2025 |
| Investor Presentation (August 2025) | Investor deck | 33 slides | Aug 21, 2025 |
Show 50 decks
This page holds 50 of 109 decks. Open Decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Ordinary bonds converted into convertible bonds (OCs) Closed: €1M raised · €9.2 · Vester Finance Dealers: Vester Finance Buyers: Vester Finance | Apr 30, 2026 | US$1.17M |
| New shares (PACEO equity line) Closed: €3.1M raised Buyers: Vester Finance (up to 5,000,000 additional shares) | Jan 5, 2026 | US$3.61M |
| Convertible bonds Closed: €3M raised · Vester Finance Dealers: Vester Finance Buyers: Vester Finance Use of proceeds: Reinforce cash position and better manage resources | Jan 5, 2026 | US$3.51M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.8M | 7.86M | 6.90M | 3.27M | 7.23M | 12.9M | 4.72M | 15.1M | 16.0K | |
| Cost of revenue | 10.2M | 1.11M | 18.4M | 18.0M | 17.9M | 12.7M | 826.0K | 12.9M | ||
| Gross profit | 6.54M | 6.75M | -11.5M | -14.7M | -10.7M | 179.0K | 3.89M | 2.13M | 16.0K | |
| Research and development | 5.96M | 7.55M | 18.0M | 17.9M | 12.7M | 17.7M | 16.3M | 9.75M | 12.2M | |
| Selling, general and administrative | 4.23M | 2.94M | 6.76M | 6.34M | 6.03M | 6.59M | 9.51M | 9.87M | 8.62M | |
| Operating income | -13.6M | -9.85M | -17.1M | -34.1M | -46.0M | -6.76M | -18.3M | -21.8M | -17.6M | -20.8M |
| Depreciation and amortization | 9.69K | 17.2K | 21.5K | 11.2M | 29.4M | 1.74M | 1.12M | 136.0K | 171.0K | 220.0K |
| EBITDA | -13.6M | -9.84M | -17.0M | -22.8M | -16.6M | -5.02M | -17.2M | -21.7M | -17.4M | -20.6M |
| Interest expense | 2.95M | 1.56M | 1.63M | 2.14M | 4.85M | 12.5M | 5.09M | 71.0K | 18.0K | 107.0K |
| Income before tax | -2.41M | -22.1M | -21.4M | -30.3M | -47.4M | -18.1M | -19.1M | -19.7M | -6.69M | |
| Income tax | -12 | 259.4K | -477.8K | -3.03M | -3.64M | 28.0K | -727.0K | -11.4M | 52.0K | |
| Net income | -2.41M | -22.4M | -20.9M | -31.3M | -43.8M | -18.1M | -18.9M | -18.4M | -3.62M | -19.0M |
| Earnings per share, basic | -0.03 | -0.45 | -0.42 | -0.62 | -117.00 | -54.00 | -0.56 | -0.62 | -0.13 | -0.80 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.15M | 10.5M | 11.3M | 27.1M | 42.0M | 47.2M | 22.1M | 41.4M | 28.9M | |
| Receivables | 3.20M | 9.95M | 37.7M | 40.5M | 1.09M | 1.72M | 1.07M | 616.0K | 44.0K | 104.0K |
| Current assets | 10.2M | 23.7M | 51.1M | 33.7M | 47.7M | 52.5M | 26.1M | 44.3M | 30.7M | |
| Property, plant and equipment | 11.0K | 26.0K | 240.0K | 1.02M | 1.17M | |||||
| Goodwill | 0 | 0 | 0 | 27.2M | 25.6M | 23.7M | 25.8M | 25.4M | 24.2M | 27.5M |
| Total assets | 10.4M | 24.4M | 53.0M | 93.2M | 114.6M | 142.3M | 138.6M | 150.8M | 148.7M | |
| Accounts payable | 675.5K | 1.65M | 2.50M | 2.54M | 3.65M | 2.42M | 5.00M | 4.28M | 1.93M | 1.34M |
| Current liabilities | 2.45M | 3.57M | 5.07M | 7.64M | 8.00M | 15.4M | 2.48M | 8.07M | 7.98M | 13.4M |
| Long-term debt | 15.1M | 25.2M | 20.0M | 21.2M | 13.4M | |||||
| Total debt | 406.3K | 17.7M | 25.2M | 26.5M | 21.5M | 19.1M | 85.0K | 50.0K | 62.0K | |
| Total liabilities | 4.35M | 21.0M | 31.6M | 40.7M | 39.1M | 41.4M | 15.4M | 24.9M | 24.0M | 44.2M |
| Shareholders' equity | 6.02M | 3.41M | 21.4M | 42.3M | 75.6M | 100.8M | 113.7M | 126.8M | 104.5M | |
| Shares outstanding | 88.1M | 49.9M | 49.9M | 50.1M | 43.1M | 37.0M | 33.7M | 29.6M | 27.0M | 23.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.1M | -18.5M | -5.39M | -16.1M | -19.1M | -12.4M | -25.7M | |||
| Capital spending | 0 | 0 | 0 | -42.0K | -8.00K | -20.0K | -95.0K | -228.0K | -77.0K | -8.00K |
| Free cash flow | -23.2M | -18.5M | -5.41M | -16.1M | -19.4M | -12.5M | -25.7M | |||
| Cash from investing | 132.0K | -175.0K | 4.95M | -95.0K | -270.0K | 60.0K | 8.82M | |||
| Cash from financing | 8.64M | 13.4M | 19.6M | 22.2M | 25.1M | 16.7M | ||||
| Share buybacks | 9.18M | -91.0K | -633.0K | -20.0K | ||||||
| Change in cash | -27.6M | -14.3M | -5.25M | 19.1M | 6.04M | -19.3M | 12.5M | -211.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Nicox Reports First Half 2026 Financial Results | Oct 30, 2026 | Results | Euronext |
| Nicox : Les données sur NCX 470 seront présentées lors du Congrès annuel 2026 de l’AAOpt | Sep 15, 2026 | Operations update | Euronext |
| Nicox annonce l’acceptation pour examen en Chine de la NDA de NCX 470 | Sep 10, 2026 | Other filings | Euronext |
| Nicox annonce l’extension de son horizon de trésorerie | Sep 1, 2026 | Operations update | Euronext |
| Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma | Aug 26, 2026 | Other filings | Euronext |
| Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension | Aug 9, 2026 | Other filings | Euronext |
Cap table
Built by 6ix from Nicox SA’s releases · as of Apr 30, 2026
- Common shares
- 98,757,645
- Fully diluted
- 98,757,645
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 98,757,645 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 98,757,645 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christine Placet | Director · Since at least Nov 5, 2026 |
| Damian Marron | Chairman of the Board of Directors · Since at least Nov 5, 2026 |
| Gavin Spencer | Chief Executive Officer · Since at least Jul 1, 2026 |
| Marc Le Bozec | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Nicox SA.